Download Chibaudel – 20-FEB-2017 CURRICULUM VITAE

CURRICULUM VITAE
Date : 20-FEB-2017
LASTNAME, Firstname
CHIBAUDEL, Benoist
Address
Franco-British Institute
Department of Medical Oncology - 4, rue Kléber
ZIP – City - Country
92300 - Levallois Perret - France
e-mail
[email protected]
Birthdate – City / Country
November 4th, 1976–Poitiers / France
French Id RPPS / CNOM
10001639730 / 92-23781
Speciality
Medical Oncology
Professional Activities
Department of Medical Oncology – Franco-British Institute, Levallois-Perret
Medical Oncologist
Assistant Head of Department of Medical Oncology (Pr Aimery de Gramont)
Department of Medical Oncology – Saint-Antoine Hospital, Assistance Publique –
Hôpitaux de Paris, Paris, France
Medical Oncologist
Since September
2014
2005-2014
GERCOR, Groupe Coopérateur Multidisciplinaire en Oncologie, Paris 11
Medical Director
Since November
2006
AFR Oncology, Preclinical and Translational Research, Paris 10
Since October
2014
Licenses
Master’s degree of Methodology and Biostatistics in Clinical Research – Paris 11
2013
Professional Qualification in Medical Oncology
2011
University Degree of Biostatistics (CESAM), Paris VI
2008
European Degree of pharmacovigilance, EudraVigilance Training Course, EMEA, London
2007
University Degree of Medical Oncology, Gustave Roussy Institute, Paris 11
2006
MedicalDegree
2005
Publications
1. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJ, Koopman M,
Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De
Gramont A, Sargent DJ, Grothey A; Analysis and Research in Cancers of the Digestive System (ARCAD)
Group. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis
of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of
the Digestive System (ARCAD) database. Lancet Oncol. 2016 Dec;17(12):1709-1719.
2. Lapeyre-Prost A, Hug de Larauze M, Chibaudel B, Garcia ML, Guering-Meyer V, Bouché O, Boucher E,
Ychou M, Dauba J, Obled S, Lièvre A, Malka D, Faroux R, Bonnet I, Taieb J, André T; Groupe Coopérateur
Multidisciplinaire en Oncologie, the Fédération Francophone de la Cancérologie Digestive, and the
UNICANCER Investigators of the PRODIGE Intergroup. Feasibility of Capecitabine and Oxaliplatin
Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal
Chibaudel – 20-FEB-2017
Cancer.Clin Colorectal Cancer. 2016 Sep;15(3):250-6
3. Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem JL, Glimelius B, Artru P, Moore
MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F. Prognostic
nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP).
Br J Cancer. 2016 Jul 26;115(3):281-9
4. Sebbagh S, Roux J, Dreyer C, Neuzillet C, de Gramont A, Orbegoso C, Hentic O, Hammel P, de Gramont A,
Raymond E, André T, Chibaudel B, Faivre S. Efficacy of a sequential treatment strategy with GEMOX-based
followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. ActaOncol. 2016 Jun 22:1-7
5. HamidouZ, Chibaudel B, Hebbar M, Hug de Larauze M, André T, Louvet C, Brusquant D, Garcia-Larnicol
ML, de Gramont A, Bonnetain F. Time to Definitive Health-Related Quality of Life Score Deterioration in
Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential DoseDense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial. PLoS One. 2016 Jun
16;11(6):e0157067
6. Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J,
André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group. Effect of Chemoradiotherapy vs
Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months
of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016 May
3;315(17):1844-53.
7. Lledo G, Huguet F, Chibaudel B, Di Fiore F, Mineur L, Galais MP, Artru P, Blondin V, Dupuis O, Abdiche
MS, Jovenin N, Pozet A, Bonnetain F, Attia M, Dahan L, de Gramont A. Chemoradiotherapywith FOLFOX
plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX. Eur J
Cancer. 2016 Feb1;56:115-121
8. Chibaudel B, Maindrault-Gœbel F, Bachet JB, Louvet C, Khalil A, Dupuis O, Hammel P, Garcia ML,
Bennamoun M, Brusquant D, Tournigand C, André T, Arbaud C, Larsen AK, Wang YW, Yeh CG, Bonnetain
F, de Gramont A. PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02
(MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
Cancer Med. 2016 Jan 24.
9. Lapeyre-Prost A, Hug de Larauze M, Chibaudel B, Garcia ML, Guering-Meyer V, Bouché O, Boucher E,
Ychou M, Dauba J, Obled S, Lièvre A, Malka D, Faroux R, Bonnet I, Taieb J, André T; Groupe Coopérateur
Multidisciplinaire en Oncologie, the Fédération Francophone de la Cancérologie Digestive, and the
UNICANCER Investigators of the PRODIGE Intergroup. Feasibility of Capecitabine and Oxaliplatin
Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal
Cancer. Clin Colorectal Cancer. 2015 Dec 2.
10. Chibaudel B, Bonnetain F, Tournigand C, de Gramont A. Maintenance treatment in metastatic colorectal
cancer. Lancet Oncol. 2015 Dec;16(16):e583-4.
11. Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, André T, de Gramont A. Therapeutic
strategy in unresectable metastatic colorectal cancer: an updated review. TherAdv Med Oncol. 2015
May;7(3):153-69.
12. André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T,
Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W,
Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF,
de Gramont A. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated
10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC
Study. J Clin Oncol. 2015 Dec 10;33(35):4176-87.
13. Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs
CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR,
Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ. Body Mass
Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical
Trials in the ARCAD Database. J Clin Oncol. 2016 Jan 10;34(2):144-50.
14. Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P,Lledo G, Viret F, Ramée
JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y,Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet
C, Larsen AK, André T, deGramont A. Bevacizumab with or without erlotinib as maintenance therapy
inpatients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label,
phase 3 trial. Lancet Oncol. 2015 Nov;16(15):1493-505.
15. Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F,A'Hern R, Bliss J, Bogaerts
J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja
E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S,
Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V,
Chibaudel – 20-FEB-2017
Thürlimann B, Untch M, van der Hage JA, van Tienhoven G,Wildiers H, Yarnold J, Bonnetain F, MathoulinPélissier S, Bellera C, Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breastcancer
trials: results of the DATECAN initiative (Definition for the Assessmentof Time-to-event Endpoints in CANcer
trials). Ann Oncol. 2015 Dec;26(12):2505-6.
16. Bachet JB, Chibaudel B, Bonnetain F, Validire P, Hammel P, André T, Louvet C;GERCOR group. A
randomized phase II study of weekly nab-paclitaxel plusgemcitabine or simplified LV5FU2 as first-line
therapy in patients withmetastatic pancreatic cancer: the AFUGEM GERCOR trial. BMC Cancer. 2015
Oct6;15:653.
17. Chibaudel B, Bonnetain F, Tournigand C, de Larauze MH, de Gramont A,Laurent-Puig P, Paget J,
Hadengue A, Notelet D, Benetkiewicz M, André T, deGramont A. STRATEGIC-1: A multiple-lines,
randomized, open-label GERCOR phase IIIstudy in patients with unresectable wild-type RAS metastatic
colorectal cancer.BMC Cancer. 2015 Jul 4;15:496.
18. Cohen R, Cervera P, Svrcek M, Dumont C, Garcia ML, Chibaudel B, de Gramont A, Pocard M, Duval A,
Fléjou JF, André T. [DNA mismatch repair and BRAF status incolorectal cancer: Interest for the therapeutic
management?]. Bull Cancer. 2015Jun;102(6 Suppl 1):S72-81.
19. Hebbar M, Chibaudel B, André T, Mineur L, Smith D, Louvet C, Dutel JL, Ychou M, Legoux JL, Mabro M,
Faroux R, Auby D, Brusquant D, Khalil A, Truant S, Hadengue A, Dalban C, Gayet B, Paye F, Pruvot FR,
Bonnetain F, de Gramont A; Group Coopérateur Multidisciplinaire en Oncologie (GERCOR) Group.
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable
metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timingwith perioperative or
postoperative chemotherapy from an open-label, randomizedphase III trial. Ann Oncol. 2015
May;26(5):1040.
20. Soularue É, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, Hentic O,Samalin E, Chibaudel B, de
Gramont A, André T; for GERCOR. Efficacy and safety of trastuzumab in combination with oxaliplatin and
fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal
junction adenocarcinoma patients: a retrospective study. Bull Cancer. 2015Apr;102(4):324-31.
21. Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F,A'Hern R, Bliss J, Bogaerts
J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B,Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja
E, Debled M, Delaloge S,Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S,
Negreiros I, Offersen BV, PenaultLlorca F, Pruneri G, Roche H, Russell NS,Schmitt F, Servent V,
Thürlimann B, Untch M, van der Hage JA, van Tienhoven G,Wildiers H, Yarnold J, Bonnetain F, MathoulinPélissier S, Bellera C,Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breastcancer
trials: results of the DATECAN initiative (Definition for the Assessmentof Time-to-event Endpoints in CANcer
trials)†. Ann Oncol. 2015 May;26(5):873-9.
22. Chibaudel B, Lacave R, Lefevre M, Soussan P, Antoine M, Périé S, Belloc JB,Banal A, Albert S, Chabolle F,
Céruse P, Baril P, Gatineau M, Housset M, MoukokoR, Benetkiewicz M, de Gramont A, Bonnetain F, Lacau
St Guily J. Induction therapywith cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in
patientswith resectablenonmetastatic stage III or IV squamous cell carcinoma of theoropharynx. A GERCOR
phase II ECHO-07 study. Cancer Med. 2015 May;4(5):721-31.
23. Hebbar M, Chibaudel B, André T, Mineur L, Smith D, Louvet C, Dutel JL, YchouM, Legoux JL, Mabro M,
Faroux R, Auby D, Brusquant D, Khalil A, Truant S,Hadengue A, Dalban C, Gayet B, Paye F, Pruvot FR,
Bonnetain F, Landi B, Flesch M,Carola E, Martin P, Vaillant E, de Gramont A; Group Coopérateur
Multidisciplinaire en Oncologie (GERCOR) Group. FOLFOX4 versus sequentialdose-dense FOLFOX7
followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach
to chemotherapy timing withperioperative or postoperative chemotherapy from an open-label, randomized
phaseIII trial. Ann Oncol. 2015 Feb;26(2):340-7.
24. Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L,
Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR,Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC,
Fuchs C, Souglakos J, Falcone A,Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer
C, Buyse M, Sargent DJ. Individual patient data analysis of progression-free survival versus overall survival
as a first-line end point for metastatic colorectal cancer inmodern randomized trials: findings from the
analysis and research in cancers ofthe digestive system database. J ClinOncol. 2015 Jan 1;33(1):22-8.
25. Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K,Lacaine F, Van Laethem JL,
Aparicio T, Aust D, Bassi C, Berger V, Chamorey E,Chibaudel B, Dahan L, De Gramont A, Delpero JR,
Dervenis C, Ducreux M, Gal J,Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche
A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J,
Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C,Mathoulin-Pélissier S, Collette L. Guidelines for
time-to-event end-pointdefinitions in trials for pancreatic cancer. Results of the DATECAN initiative(Definition
for the Assessment of Time-to-event End-points in CANcer trials). EurJ Cancer. 2014 Nov;50(17):2983-93.
Chibaudel – 20-FEB-2017
26. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L,Goldberg RM, Sargent
DJ, Eckhardt SG, Eng C; Aide et Recherche en CancérologieDigestive Foundation. Association of age with
survival in patients withmetastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.
JClinOncol. 2014 Sep 20;32(27):2975-84.
27. Diouf M, Chibaudel B, Filleron T, Tournigand C, Hug de Larauze M,Garcia-Larnicol ML, Dumont S, Louvet C,
Perez-Staub N, Hadengue A, de Gramont A, Bonnetain F. Could baseline health-related quality of life (QoL)
predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1study.
Health Qual Life Outcomes. 2014 May 13;12:69.
28. Manceau G, Imbeaud S, Thiébaut R, Liébaert F, Fontaine K, Rousseau F, GéninB, Le Corre D, Didelot A,
Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B,Bibeau F, Leroy K, Penault-Llorca F, Van Laethem
JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V,
AndréT, Laurent-Puig P. Hsa-miR-31-3p expression is linked to progression-freesurvival in patients with
KRAS wild-type metastatic colorectal cancer treatedwith anti-EGFR therapy. Clin Cancer Res. 2014 Jun
15;20(12):3338-47.
29. Vignot S, Thariat J; Étienne Bardet (GORTEC et coordinateur del’intergroupe), Juliette Thariat (GORTEC),
Dominique De Raucourt (GETTEC), FranckJegoux (GETTEC), François Janot (GETTEC), Jean Lacau
(GERCOR), Dominique Notelet (GERCOR), Benoist Chibaudel (GERCOR), NadejdaVintonenko (manager
Intergroupe),Jean Bourhis (GORTEC). [Otorhinolaryngology thematic issue. Presentation]. BullCancer. 2014
May;101(5):399.
30. Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, AuquierP, Westeel V, Fiteni F, Borg C,
Bonnetain F. Time to health-related quality oflife score deterioration as a modality of longitudinal analysis
forhealth-related quality of life studies in oncology: do we need RECIST for qualityof life to achieve
standardization? Qual Life Res. 2015 Jan;24(1):5-18.
31. Thariat J, Jegoux F, Pointreau Y, Fayette J, Boisselier P, Blanchard P,Alfonsi M, Aupérin A, Bardet E,
Bensadoun RJ, Garaud P, Geoffrois L, Graff P,Guigay J, Janot F, Lapeyre M, Lefebvre JL, Martin L,
Racadot S, Rolland F, SireC, Tao Y, Tuchais C, Chibaudel B, Girard-Calais MH, Cornely A, Vintonenko
N,Calais G, De Raucourt D, Lacau Saint-Guily J, Bourhis J. [Advances in head andneck cancers on behalf of
the French Intergroup ORL and GORTEC]. Bull Cancer.2013 Oct;100(10):983-97.
32. André T, Chibaudel B. [Aflibercept (Zaltrap(®)) approved in metastaticcolorectal cancer]. Bull Cancer. 2013
Oct;100(10):1023-5.
33. Chibaudel B, Tournigand C, Bonnetain F, Maindrault-Goebel F, Lledo G, AndréT, Larsen AK, BengrineLefevre L, Louvet C, de Gramont A. Platinum-sensitivity inmetastatic colorectal cancer: towards a definition.
Eur J Cancer. 2013Dec;49(18):3813-20.
34. Hebbar M, Chibaudel B, André T, Louvet C, Smith D, Mineur L, Bennamoun M,Mabro M, Brusquant D,
Bonnetain F, Pruvot FR, de Gramont A. Randomized trial ofsimplified LV5FU2 versus FOLFOX7 followed by
FOLFIRI (MIROX) in patients withinitially resectable metastatic colorectal cancer: a GERCOR study. J
Chemother.2013 Apr;25(2):104-11.
35. Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P,Desseigne F, Bachet JB, Mathiot
C, Pierga JY, Hammel P. Circulating tumor cellsin locally advanced pancreatic adenocarcinoma: the ancillary
CirCe 07 study tothe LAP 07 trial. Ann Oncol. 2013 Aug;24(8):2057-61.
36. André T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C, Bennamoun M,Artru P, Nguyen S,
Ebenezer C, Aissat N, Cayre A, Penault-Llorca F, Laurent-Puig P, de Gramont A; GERCOR. Panitumumab
combined with irinotecan for patients withKRAS wild-type metastatic colorectal cancer refractory to standard
chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol. 2013
37. Feb;24(2):412-9.
38. Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T,Tabernero J, Boni C, Bachet JB,
Teixeira L, de Gramont A. Adjuvant therapy withfluorouracil and oxaliplatin in stage II and elderly patients
(between ages 70and 75 years) with colon cancer: subgroup analyses of the MulticenterInternational Study
of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J ClinOncol.
2012 Sep 20;30(27):3353-60.
39. Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy inunresectable metastatic
colorectal cancer. TherAdv Med Oncol. 2012Mar;4(2):75-89.
40. de Gramont A, de Gramont A, Chibaudel B, Larsen AK, Tournigand C, André T;GERCOR French Oncology
Research Group. The evolution of adjuvant therapy in thetreatment of early-stage colon cancer. Clin
Colorectal Cancer. 2011Dec;10(4):218-26.
41. Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, AllegraCJ, Goldberg RM, de
Chibaudel – 20-FEB-2017
Gramont A. Alternative end points to evaluate a therapeuticstrategy in advanced colorectal cancer:
evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide
etRecherche enCancerologie Digestive Group Study. J ClinOncol. 2011 Nov1;29(31):4199-204.
42. Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Mégalophonos VF,Kamsu-Kom N, Petitprez A,
Escargueil AE, Boudou P, Dumont S, Cervera P, FléjouJF, André T, Tournigand C, Chibaudel B, de
Gramont A, Larsen AK. EGFR- andVEGF(R)-targeted small molecules show synergistic activity in colorectal
cancermodels refractory to combinations of monoclonal antibodies. Clin Cancer Res. 2011Oct
15;17(20):6522-30.
43. Chibaudel B, Bonnetain F, Tournigand C, Bengrine-Lefevre L, Teixeira L, ArtruP, Desramé J, Larsen AK,
André T, Louvet C, de Gramont A. Simplified prognosticmodel in patients with oxaliplatin-based or
irinotecan-based first-linechemotherapy for metastatic colorectal cancer: a GERCOR study.
Oncologist.2011;16(9):1228-38.
44. 37: de Gramont A, de Gramont A, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, Louvet C, André T;
GERCOR (French Oncology Research Group). From chemotherapy to targeted therapy in adjuvant
treatment for stage III colon cancer. SeminOncol.2011 Aug;38(4):521-32.
45. Bengrine-Lefevre L, Afchain P, Chibaudel B, Gervais H, Tournigand C, DeGramont A, Louvet C. [Nasal
septum perforation and bevacizumab]. Rev Med Interne.2011 Apr;32(4):e43-5.
46. Chibaudel B, Tournigand C, André T, Larsen AK, de Gramont A. Targetedtherapies as adjuvant treatment
for early-stage colorectal cancer: firstimpressions and clinical questions. Clin Colorectal Cancer. 2010
Dec;9(5):269-73.
47. Tournigand C, Bengrine-Lefevre L, Chibaudel B, de Gramont A. [Management ofmetastatic colorectal
cancer]. Rev Prat. 2010 Oct 20;60(8):1103-7. French.
48. Rousseau B, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, Louvet C, AndréT, de Gramont A;
GERCOR (French Oncology Research Group). Stage II and stage IIIcolon cancer: treatment advances and
future directions. Cancer J. 2010May-Jun;16(3):202-9.
49. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL,Francoual M, Lledo G,
André T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A. Methylenetetrahydrofolate reductase
(MTHFR) gene polymorphisms and FOLFOXresponse in colorectal cancer patients. Br J ClinPharmacol.
2010Jan;69(1):58-66.
50. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M,Mabro M, Artru P, Carola E,
Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P,Tournigand C, Louvet C, de Gramont A. Can
chemotherapy be discontinued inunresectable metastatic colorectal cancer? The GERCOR OPTIMOX2
Study. J ClinOncol. 2009 Dec 1;27(34):5727-33.
51. Chibaudel B, Tournigand C, Artru P, André T, Cervantes A, Figer A, Lledo G,Flesch M, Buyse M, Mineur L,
Carola E, Rivera F, Perez-Staub N, Louvet C, deGramont A. FOLFOX in patients with metastatic colorectal
cancer and high alkalinephosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. Ann
Oncol.2009 Aug;20(8):1383-6.
52. Afchain P, Chibaudel B, Lledo G, Selle F, Bengrine-Lefevre L, Nguyen S,Paitel JF, Mineur L, Artru P, André
T, Louvet C. First-line simplified GEMOX(S-GemOx) versus classical GEMOX in metastatic pancreatic
cancer (MPA): resultsof a GERCOR randomized phase II study. Bull Cancer. 2009 May;96(5):E18-22.
Clinical, Translational and Pre-clinical Research
Investigator Site Personnel ICH GCP Training Certificate (26-JUN-2015)
Coordinator / chairman of national & international prospective studies (phases I, II & III)
Principal Investigator (PI) of national and international studies (phase I, II & III)
Responsible of Pharmacovigilance Unit (GERCOR)
Member of INSERM U938, Hôpital Saint-Antoine, Paris 12, France
Member of AFR Oncology, Paris 10, France
Member of Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR), Paris, France
Member of ARCAD Group, Fondation d’Aide et Recherche en CAncérologie Digestive (A.R.CA.D)
Chibaudel – 20-FEB-2017
Member European Society of Medical Oncology (ESMO)
Member of American Society of Clinical Oncology (ASCO)
Expert assessment for the French National Health Authority (Agence Nationale de Sécurité du Médicament et
des produits de santé (ANSM), France)
February 20, 2017
Dr Benoist CHIBAUDEL
Chibaudel – 20-FEB-2017